The role of metabolic setting in predicting the risk of early tumour relapse of differentiated thyroid cancer (DTC).
Journal
European journal of clinical nutrition
ISSN: 1476-5640
Titre abrégé: Eur J Clin Nutr
Pays: England
ID NLM: 8804070
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
03
04
2020
accepted:
28
05
2020
revised:
23
05
2020
pubmed:
11
6
2020
medline:
25
6
2021
entrez:
11
6
2020
Statut:
ppublish
Résumé
The role of insulin resistance and adipocytokines in determining the phenotype and recurrence of differentiated thyroid cancer (DTC) is still unknown. In a previous study, we observed an association between metabolic setting, circulating adipocytokines and thyroid cancer phenotype. The aim of this study was to evaluate the clinical follow-up of patients with DTC and the predictive role of metabolic setting on the risk of tumour relapse. Between September 2016 and January 2017, 57 patients were admitted to our institution to undergo total thyroidectomy because of suspected DTC. Thirty patients with post-surgical histological diagnosis of DTC were included in the study. Each subject underwent pre-surgical analysis of anthropometric parameters, thyroid function and autoimmunity, glucose metabolism, insulin resistance (HOMA-IR) and levels of unacylated and acylated ghrelin, obestatin, leptin and adiponectin. Tumour recurrence at 1 and 3 years from diagnosis was assessed. Most patients were females (21F, 9M) with a median age at diagnosis of 50.0 (41.0-58.8). At baseline, overweight was found in 7 patients and obesity in 6 cases. Insulin resistance was detected in 14 patients. Overall, 17 patients (56.7%) underwent radioiodine treatment after surgery. During the follow-up, we observed a persistent biochemical disease in one patient whereas tumour relapse was found in six patients at 1 year from diagnosis (lymph node metastases) and in one patient at 3 years from diagnosis (lung metastases). Independently from age, sex, stage of disease and the presence of lymph node metastasis at diagnosis, higher BMI, leptin and insulin levels as well as HOMA-IR were associated with a higher risk of tumour relapse (p < 0.05 for all). Our results highlight a possible role for BMI, leptin and insulin resistance as predictors of early DTC relapse.
Sections du résumé
BACKGROUND
The role of insulin resistance and adipocytokines in determining the phenotype and recurrence of differentiated thyroid cancer (DTC) is still unknown. In a previous study, we observed an association between metabolic setting, circulating adipocytokines and thyroid cancer phenotype. The aim of this study was to evaluate the clinical follow-up of patients with DTC and the predictive role of metabolic setting on the risk of tumour relapse.
METHODS
Between September 2016 and January 2017, 57 patients were admitted to our institution to undergo total thyroidectomy because of suspected DTC. Thirty patients with post-surgical histological diagnosis of DTC were included in the study. Each subject underwent pre-surgical analysis of anthropometric parameters, thyroid function and autoimmunity, glucose metabolism, insulin resistance (HOMA-IR) and levels of unacylated and acylated ghrelin, obestatin, leptin and adiponectin. Tumour recurrence at 1 and 3 years from diagnosis was assessed.
RESULTS
Most patients were females (21F, 9M) with a median age at diagnosis of 50.0 (41.0-58.8). At baseline, overweight was found in 7 patients and obesity in 6 cases. Insulin resistance was detected in 14 patients. Overall, 17 patients (56.7%) underwent radioiodine treatment after surgery. During the follow-up, we observed a persistent biochemical disease in one patient whereas tumour relapse was found in six patients at 1 year from diagnosis (lymph node metastases) and in one patient at 3 years from diagnosis (lung metastases). Independently from age, sex, stage of disease and the presence of lymph node metastasis at diagnosis, higher BMI, leptin and insulin levels as well as HOMA-IR were associated with a higher risk of tumour relapse (p < 0.05 for all).
CONCLUSIONS
Our results highlight a possible role for BMI, leptin and insulin resistance as predictors of early DTC relapse.
Identifiants
pubmed: 32518296
doi: 10.1038/s41430-020-0671-y
pii: 10.1038/s41430-020-0671-y
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1038-1046Références
Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15:556–65.
pubmed: 20507889
pmcid: 3227989
doi: 10.1634/theoncologist.2009-0285
Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.
pubmed: 30253139
doi: 10.1016/j.metabol.2018.09.005
Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid cancer. Endocrinol Metab Clin North Am. 2019;48:23–35.
pubmed: 30717905
doi: 10.1016/j.ecl.2018.10.002
Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12:646–53.
pubmed: 27418023
doi: 10.1038/nrendo.2016.110
Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes. 2017;24:332–6.
pubmed: 28692457
pmcid: 5864110
doi: 10.1097/MED.0000000000000359
Pazaitou-Panayiotou K, Iliadou PK, Chrisoulidou A, Mitsakis P, Doumala E, Fotareli A, et al. The increase in thyroid cancer incidence is not only due to papillary microcarcinomas: a 40-year study in 1778 patients. Exp Clin Endocrinol Diabetes. 2013;121:397–401.
pubmed: 23696480
doi: 10.1055/s-0033-1345125
Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.
pubmed: 23737785
pmcid: 3664492
doi: 10.1155/2013/965212
Pagano L, Mele C, Arpaia D, Samà MT, Caputo M, Ippolito S, et al. How do etiological factors can explain the different clinical features of patients with differentiated thyroid cancer and their histopathological findings? Endocrine. 2017;56:129–37.
pubmed: 27230768
doi: 10.1007/s12020-016-0992-8
Barrea L, Gallo M, Ruggeri RM, Giacinto PD, Sesti F, Prinzi N, et al. E.O.L.O. Group. Nutritional status and follicular-derived thyroid cancer: an update. Crit Rev Food Sci Nutr. 2020;30:1–35.
Marcello MA, Cunha LL, Batista FA, Ward LS. Obesity and thyroid cancer. Endocr Relat Cancer. 2014;21:T255–271.
pubmed: 24741026
doi: 10.1530/ERC-14-0070
Santini F, Marzullo P, Rotondi M, Ceccarini G, Pagano L, Ippolito S, et al. Mechanisms in endocrinology: the crosstalk between thyroid gland and adipose tissue: signal integration in health and disease. Eur J Endocrinol. 2014;171:R137–152.
pubmed: 25214234
doi: 10.1530/EJE-14-0067
Vigneri R, Goldfine ID, Frittitta L. Insulin, insulin receptors, and cancer. J Endocrinol Invest. 2016;39:1365–76.
pubmed: 27368923
doi: 10.1007/s40618-016-0508-7
Mele C, Samà MT, Bisoffi AA, Caputo M, Bullara V, Mai S, et al. Circulating adipokines and metabolic setting in differentiated thyroid cancer. Endocr Connect. 2019;8:997–1006.
pubmed: 31252407
pmcid: 6652238
doi: 10.1530/EC-19-0262
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–83.
pubmed: 16998510
doi: 10.1038/nri1937
Cheng SP, Yin PH, Hsu YC, Chang YC, Huang SY, Lee JJ, et al. Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways. Oncol Rep. 2011;26:1265–71.
pubmed: 21750869
Uddin S, Bavi P, Siraj AK, Ahmed M, Al-Rasheed M, Hussain AR, et al. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr Relat Cancer. 2010;17:191–202.
pubmed: 20008098
doi: 10.1677/ERC-09-0153
Tumminia A, Vinciguerra F, Parisi M, Graziano M, Sciacca L, Baratta R, et al. Adipose tissue, obesity and adiponectin: role in endocrine cancer risk. Int J Mol Sci. 2019;20:E2863. pii
pubmed: 31212761
doi: 10.3390/ijms20122863
Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, Moon HS, Chamberland JP, Liu X, et al. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab. 2011;96:E2023–2028.
pubmed: 21937620
pmcid: 3232611
doi: 10.1210/jc.2010-1908
Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ. Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys. 2013;65:203–10.
pubmed: 22907586
doi: 10.1007/s12013-012-9419-1
Karaoglu A, Aydin S, Dagli AF, Cummings DE, Ozercan IH, Canatan H, et al. Expression of obestatin and ghrelin in papillary thyroid carcinoma. Mol Cell Biochem. 2009;323:113–8.
pubmed: 19039650
doi: 10.1007/s11010-008-9969-0
Nardi F, Basolo F, Crescenzi A, Fadda G, Frasoldati A, Orlandi F, et al. Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest. 2014;37:593–9.
pubmed: 24789536
doi: 10.1007/s40618-014-0062-0
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.
pubmed: 26462967
pmcid: 4739132
doi: 10.1089/thy.2015.0020
Matrone A, Latrofa F, Torregrossa L, Piaggi P, Gambale C, Faranda A, et al. Changing trend of thyroglobulin antibodies in patients with differentiated thyroid cancer treated with total thyroidectomy without (131)I ablation. Thyroid. 2018;28:871–9.
pubmed: 29860933
doi: 10.1089/thy.2018.0080
World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity. Geneva: WHO Technical Report Series n. 894, 2000
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
pubmed: 3899825
doi: 10.1007/BF00280883
Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15–26.
pubmed: 17957034
doi: 10.1152/ajpendo.00645.2007
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A. AJCC Cancer Staging Handbook. From the AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010.
Tuttle M, Morris LF, Haugen B, Shah J, Sosa JA, Rohren E et al. Thyroid differentiated and anaplastic carcinoma. In: AJCC Cancer Staging Manual. 8th ed., New York, NY: Springer International Publishing, 2017, Chapter 73.
Yin DT, He H, Yu K, Xie J, Lei M, Ma R, et al. The association between thyroid cancer and insulin resistance, metabolic syndrome and its components: a systematic review and meta-analysis. Int J Surg. 2018;57:66–75.
pubmed: 30081182
doi: 10.1016/j.ijsu.2018.07.013
Malaguarnera R, Vella V, Nicolosi ML, Belfiore A. Insulin resistance: any role in the changing epidemiology of thyroid cancer? Front Endocrinol (Lausanne). 2017;8:314.
pubmed: 29184536
pmcid: 5694441
doi: 10.3389/fendo.2017.00314
Rezzonico JN, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord. 2009;7:375–80.
pubmed: 19320560
doi: 10.1089/met.2008.0062
Bae MJ, Kim SS, Kim WJ, Yi YS, Jeon YK, Kim BH, et al. High prevalence of papillary thyroid cancer in Korean women with insulin resistance. Head Neck. 2016;38:66–71.
pubmed: 25196854
doi: 10.1002/hed.23848
Trésallet C, Seman M, Tissier F, Buffet C, Lupinacci RM, Vuarnesson H, et al. The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices. Surgery. 2014;156:1145–52.
pubmed: 24878452
doi: 10.1016/j.surg.2014.04.020
Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab. 2012;97:1134–45.
pubmed: 22278420
doi: 10.1210/jc.2011-2735
Pitoia F, Abelleira E, Bueno F, Urciuoli C, Schmidt A, Niepomniszcze H. Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer. Endocrine. 2015;48:894–901.
pubmed: 25209891
doi: 10.1007/s12020-014-0416-6
Inoue M, Tsugane S. Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer. 2012;19:F1–F8.
pubmed: 22851686
doi: 10.1530/ERC-12-0142
Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, et al. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab. 2002;87:245–54.
pubmed: 11788654
doi: 10.1210/jcem.87.1.8142
Malaguarnera R, Frasca F, Garozzo A, Gianı F, Pandini G, Vella V, et al. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab. 2011;96:766–74.
pubmed: 21123448
doi: 10.1210/jc.2010-1255
Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol. 2014;220:T1–T23.
pubmed: 24281010
pmcid: 4087161
doi: 10.1530/JOE-13-0584
Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck G. Adipose tissue immunity and cancer. Front Physiol. 2013;4:275.
pubmed: 24106481
pmcid: 3788329
doi: 10.3389/fphys.2013.00275
Cunha LL, Marcello MA, Ward LS. The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocr Relat Cancer. 2014;21:R85–R103.
pubmed: 24302667
doi: 10.1530/ERC-13-0431
Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4:71.
doi: 10.3389/fendo.2013.00071
Crean-Tate KK, Reizes O. Leptin regulation of cancer stem cells in breast and gynecologic cancer. Endocrinology. 2018;159:3069–80.
pubmed: 29955847
pmcid: 6669812
doi: 10.1210/en.2018-00379
Ghasemi A, Saeidi J, Azimi-Nejad M, Hashemy SI. Leptin-induced signaling pathways in cancer cell migration and invasion. Cell Oncol (Dordr). 2019;42:243–60.
pubmed: 30877623
doi: 10.1007/s13402-019-00428-0
Celano M, Maggisano V, Lepore SM, Sponziello M, Pecce V, Verrienti A, et al. Expression of leptin receptor and effects of leptin on papillary thyroid carcinoma cells. Int J Endocrinol. 2019;2019:5031696.
pubmed: 30906321
pmcid: 6393892
doi: 10.1155/2019/5031696
Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33:547–94.
pubmed: 22547160
pmcid: 3410224
doi: 10.1210/er.2011-1015
Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D. LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene. 2009;28:2621–33.
pubmed: 19483724
pmcid: 2945727
doi: 10.1038/onc.2009.129
Wu X, Yan Q, Zhang Z, Du G, Wan X. Acrp30 inhibits leptin-induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells. Oncol Rep. 2012;27:1488–96.
pubmed: 22327423
doi: 10.3892/or.2011.1586
Volante M, Rosas R, Ceppi P, Rapa I, Cassoni P, Wiedenmann B, et al. Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. J Pathol. 2009;218:458–66.
pubmed: 19373849
doi: 10.1002/path.2551
Gurgul E, Kasprzak A, Blaszczyk A, Biczysko M, Surdyk-Zasada J, Seraszek-Jaros A, et al. Ghrelin and obestatin in thyroid gland—immunohistochemical expression in nodular goiter, papillary and medullary cancer. Folia Histochem Cytobiol. 2015;53:19–25.
pubmed: 25765090
doi: 10.5603/FHC.a2015.0004